LE WE PMID CA
Osteoporosis2070Osteoporose

Alendronate

Bariatric surgery

Bisphosphonates

Bone (Metastasis)

Bone (Traumatology)

Bortezomib ttProteasom

Calcium (Hypercalciuria)

CathepsinK

Clodronate

COPD

Dickkopf1

Etidronate

Glucocorticoids

Hypercalciuria idiopathic

Inflammation (BASKET)

Lasofoxifene

LRP5 LDL Receptor Related Protein5 Arrow

Mammary gland (Neoplasia)

Neoplasia (Cancer survivor)

Neoplasia (Tumor biology and immunology)

Nephrolithiasis

Obesity (BASKET)

Odanacatib

Orthopanography

Osteoblasts

Osteoclasts

Osteoporosis

PCD (Multiple myeloma and other plasma cell dyscrasias)

PTH (Parathyroid hormone)

Raloxifene

Risedronate

SERM

Spine (Kyphoplasty and Vertebroplasty)

Spine and spinal cord (Traumatology)

Strontium ranelate

Sympathetic nervous system

Systemic lupus erythematosus

Teriparatide

Testosterone

Thalidomide

Vitamin D

Wnt beta Catenin TCF

Zoledronic acid

2006  
1
Osteoporosis and its management.
[17170416] BMJ 333(7581): 1251-6 (2006)
2000  
2
Osteoporosis: epidemiology, diagnosis, and treatment.
[10653058] South Med J 93(1): 2-18 (2000)
2009  
3
Managing osteoporosis: challenges and strategies.
[19652039] Cleve Clin J Med 76(8): 457-66 (2009)
2008  
4
Using biochemical markers of bone turnover in clinical practice.
[18939390] Cleve Clin J Med 75(10): 739-50 (2008)
2008  
5
Clinical challenges in the management of osteoporosis.
[18686753] Clin Interv Aging 3(2): 315-29 (2008)
2007  
6
Teriparatide in the management of osteoporosis.
[18225450] Clin Interv Aging 2(4): 499-507 (2007)
2001  
7
Diagnostic challenges in osteoporosis. Indications for bone densitometry and establishing secondary causes.
[11421053] Can Fam Physician 47(-): 1244-50 (2001)
2008  
8
The diagnosis and treatment of primary osteoporosis according to current guidelines.
[19471676] Dtsch Arztebl Int 105(33): 573-81; quiz 581-2 (2008)
2010  
9
Odanacatib, a new drug for the treatment of osteoporosis: review of the results in postmenopausal women.
[20948576] J Osteoporos 2010(-): - (2010)
2009  
10
Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis.
[19898646] Ther Clin Risk Manag 5(-): 817-27 (2009)
2007  
11
Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis.
[17311734] Health Technol Assess 11(7): iii-iv, ix-xi, 1-231 (2007)
2005  
12
A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
[15929857] Health Technol Assess 9(22): 1-160 (2005)
2002  
13
Treatment of established osteoporosis: a systematic review and cost-utility analysis.
[12654239] Health Technol Assess 6(29): 1-146 (2002)
2010  
14
Lasofoxifene: Evidence of its therapeutic value in osteoporosis.
[20694069] Core Evid 4(-): 113-29 (2010)
2010  
15
Intravenous zoledronic acid for the treatment of osteoporosis: The evidence of its therapeutic effect.
[20694061] Core Evid 4(-): 13-23 (2010)
2009  
16
Developments in the scientific understanding of osteoporosis.
[19497136] Arthritis Res Ther 11(3): 228 (2009)
2001  
17
2007  
18
Osteopenia and cancer in children and adolescents: the fragility of success.
[17326055] Cancer 109(7): 1420-31 (2007)
2008  
19
Cancer treatment-induced bone loss: pathophysiology and clinical perspectives.
[18305064] Oncologist 13(2): 187-95 (2008)
2006  
20
Bone loss and fracture risk associated with cancer therapy.
[17110632] Oncologist 11(10): 1121-31 (2006)
2001  
21
2008  
22
2005  
23
Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.
[15769903] Endocr Rev 26(5): 688-703 (2005)
2005  
24
Biochemical markers of bone turnover: part I: biochemistry and variability.
[16648882] Clin Biochem Rev 26(4): 97-122 (2005)
2007  
25
An integrated approach: bisphosphonate management for the treatment of osteoporosis.
[18095779] Am J Manag Care 13 Suppl 11(-): S290-308; quiz S309-12 (2007)
2004  
26
Medical management of osteoporosis.
[15298366] Am J Manag Care 10(7 Pt 1): 445-55 (2004)
2001  
27
Evaluation and treatment of postmenopausal osteoporosis.
[11599675] Am J Manag Care 7 Spec No(-): SP5-16 (2001)
2001  
28
Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis.
[11465699] Arthritis Rheum 44(7): 1496-503 (2001)
1999  
29
The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach.
[10446876] Arthritis Rheum 42(8): 1740-51 (1999)
2008  
30
Management of osteoporosis in children.
[18772270] Eur J Endocrinol 159 Suppl 1(-): S33-9 (2008)
1997  
31
Glucocorticoid osteoporosis--mechanisms and management.
[9330580] Eur J Endocrinol 137(3): 209-17 (1997)
2000  
32
Guidelines for osteoporosis in coeliac disease and inflammatory bowel disease. British Society of Gastroenterology.
[10647595] Gut 46 Suppl 1(-): i1-8 (2000)
2005  
33
Pathogenesis of osteoporosis: concepts, conflicts, and prospects.
[16322775] J Clin Invest 115(12): 3318-25 (2005)
2001  
34
Osteoporosis in men: a cellular endocrine perspective of an increasingly common clinical problem.
[11241167] J Endocrinol 168(3): 353-62 (2001)
2007  
35
Combined therapies in osteoporosis: bisphosphonates and vitamin D-hormone analogs.
[17627088] J Musculoskelet Neuronal Interact 7(2): 174-84 (2007)
2002  
36
Clinical use of bone densitometry: clinical applications.
[12377089] JAMA 288(15): 1898-900 (2002)
2002  
37
Clinical use of bone densitometry: scientific review.
[12377088] JAMA 288(15): 1889-97 (2002)
2006  
38
Diagnosis, screening, prevention, and treatment of osteoporosis.
[16706264] Mayo Clin Proc 81(5): 662-72 (2006)
2002  
39
Secondary causes of osteoporosis.
[12004995] Mayo Clin Proc 77(5): 453-68 (2002)
2002  
40
2002  
41
Osteoporosis prophylaxis during corticosteroid treatment: failure to prescribe.
[11930029] Postgrad Med J 78(918): 242-3 (2002)
2002  
42
Management of corticosteroid-induced osteoporosis.
[12364625] Rheumatology (Oxford) 41(10): 1088-94 (2002)
1991  
43
1991  
44
2008  
45
Osteoporosis in celiac disease and in endocrine and reproductive disorders.
[18203279] World J Gastroenterol 14(4): 498-505 (2008)
2007  
46
Basic and clinical aspects of osteoporosis in inflammatory bowel disease.
[18069754] World J Gastroenterol 13(46): 6156-65 (2007)
2006  
47
Parathyroid hormone for the treatment of osteoporosis: a systematic review.
[16818910] CMAJ 175(1): 52-9 (2006)
2006  
48
Clinical practice guidelines for the use of parathyroid hormone in the treatment of osteoporosis.
[16818909] CMAJ 175(1): 48 (2006)
2010  
49
2010  
50
High-resolution imaging techniques for the assessment of osteoporosis.
[20609895] Radiol Clin North Am 48(3): 601-21 (2010)
2007  
51
2007  
52
Osteoporosis: integrating biomarkers and other diagnostic correlates into the management of bone fragility.
[17604458] Altern Med Rev 12(2): 113-45 (2007)
2010  
53
How to prevent glucocorticoid-induced osteoporosis.
[20682515] Cleve Clin J Med 77(8): 529-36 (2010)
2008  
54
Biochemical markers of bone turnover: useful but underused.
[18939391] Cleve Clin J Med 75(10): 751-2 (2008)
2010  
55
Osteoporosis - new treatments and updates.
[20969546] Bull NYU Hosp Jt Dis 68(3): 166-70 (2010)
2008  
56
Treatment strategies for patients with low bone mass: the younger postmenopausal female.
[18937639] Bull NYU Hosp Jt Dis 66(3): 240-3 (2008)
2011  
57
Update on medications with adverse skeletal effects.
[21389249] Mayo Clin Proc 86(4): 338-43; quiz 343 (2011)
2004  
58
Recognizing and treating glucocorticoid-induced osteoporosis in patients with pulmonary diseases.
[15136401] Chest 125(5): 1859-76 (2004)
2007  
59
Comparing pain reduction following kyphoplasty and vertebroplasty for osteoporotic vertebral compression fractures.
[17660858] Pain Physician 10(4): 583-90 (2007)
2002  
60
Clinical review 151: The role of parathyroid hormone in the pathogenesis of glucocorticoid-induced osteoporosis: a re-examination of the evidence.
[12213840] J Clin Endocrinol Metab 87(9): 4033-41 (2002)
2010  
61
Long-term use of bisphosphonates in osteoporosis.
[20173017] J Clin Endocrinol Metab 95(4): 1555-65 (2010)
2010  
62
Approach to the patient with secondary osteoporosis.
[20231368] Eur J Endocrinol 162(6): 1009-20 (2010)
2011  
63
Osteoblasts in osteoporosis: past, emerging, and future anabolic targets.
[21543379] Eur J Endocrinol 165(1): 1-10 (2011)
2010  
64
2004  
65
2007  
66
Myeloma bone disease and proteasome inhibition therapies.
[17494860] Blood 110(4): 1098-104 (2007)
2009  
67
The role of Dickkopf-1 in bone development, homeostasis, and disease.
[18687985] Blood 113(3): 517-25 (2009)
2008  
68
Pharmacological topics of bone metabolism: the physiological function of the sympathetic nervous system in modulating bone resorption.
[18431037] J Pharmacol Sci 106(4): 542-6 (2008)
2008  
69
Pharmacological topics of bone metabolism: recent advances in pharmacological management of osteoporosis.
[18431035] J Pharmacol Sci 106(4): 530-5 (2008)
2010  
70
2011  
71
Parathyroid hormone versus bisphosphonate treatment on bone mineral density in osteoporosis therapy: a meta-analysis of randomized controlled trials.
[22022584] PLoS One 6(10): e26267 (2011)
2010  
72
Bone loss across the menopausal transition.
[20392219] Ann N Y Acad Sci 1192(-): 66-71 (2010)
2010  
73
Bone turnover across the menopause transition : The role of gonadal inhibins.
[20392231] Ann N Y Acad Sci 1192(-): 153-60 (2010)
2009  
74
Osteoporosis in patients with systemic lupus erythematosus.
[19891237] Isr Med Assoc J 11(8): 486-91 (2009)
2003  
75
2007  
76
The role of DXA bone density scans in the diagnosis and treatment of osteoporosis.
[17675543] Postgrad Med J 83(982): 509-17 (2007)
2011  
77
Early diagnosis of osteoporosis by means of orthopantomograms and oral x-rays: a systematic review.
[21743400] Med Oral Patol Oral Cir Bucal 16(7): e905-13 (2011)
2010  
78
2010  
79
Bariatric surgery and bone metabolism: a systematic review.
[20485904] Arq Bras Endocrinol Metabol 54(2): 158-63 (2010)
2010  
80
SERMs in the prevention and treatment of postmenopausal osteoporosis: an update.
[20485909] Arq Bras Endocrinol Metabol 54(2): 200-5 (2010)
2010  
81
Bisphosphonates in the treatment of metabolic bone diseases.
[20485910] Arq Bras Endocrinol Metabol 54(2): 206-12 (2010)
2010  
82
The use of PTH in the treatment of osteoporosis.
[20485911] Arq Bras Endocrinol Metabol 54(2): 213-9 (2010)
2007  
83
Glucocorticoid-induced osteoporosis: clinical and therapeutic aspects.
[18209880] Arq Bras Endocrinol Metabol 51(8): 1404-12 (2007)
2006  
84
2006  
85
2006  
86
Low bone mass in children and adolescents.
[17117302] Arq Bras Endocrinol Metabol 50(4): 775-82 (2006)
2006  
87
2006  
88
2006  
89
Anabolic skeletal therapy for osteoporosis.
[17117299] Arq Bras Endocrinol Metabol 50(4): 745-54 (2006)
2006  
90
2006  
91
Estrogen therapy for postmenopausal osteoporosis.
[17117296] Arq Bras Endocrinol Metabol 50(4): 705-19 (2006)
2006  
92
Redefining osteoporosis treatment: Who to treat and how long to treat.
[17117295] Arq Bras Endocrinol Metabol 50(4): 694-704 (2006)
2006  
93
Office practice of osteoporosis evaluation.
[17117293] Arq Bras Endocrinol Metabol 50(4): 674-84 (2006)
2010  
94
2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary.
[20940232] CMAJ 182(17): 1864-73 (2010)
2011  
95
Management and Treatment of Osteoporosis in Patients Receiving Long-term Glucocorticoid Treatment: Current Status of Adherence to Clinical Guidelines and Related Factors.
[22082891] Intern Med 50(22): 2793-800 (2011)
2005  
96
The prevention and treatment of osteoporosis: a review.
[16369451] MedGenMed 7(2): 73 (2005)
2009  
97
Current status of research on osteoporosis in COPD: a systematic review.
[19567604] Eur Respir J 34(1): 209-18 (2009)
2002  
98
Treatment of osteoporotic fractures.
[12164513] Scand J Surg 91(2): 140-6 (2002)
2003  
99
Invited Review: Pathogenesis of osteoporosis.
[14555675] J Appl Physiol 95(5): 2142-51 (2003)
2011  
100
Effects of glucocorticoids on growth and bone mineralization.
[21234507] J Pediatr (Rio J) 87(1): 4-12 (2011)
2006  
101
Strontium ranelate: a novel treatment for postmenopausal osteoporosis: a review of safety and efficacy.
[18046914] Clin Interv Aging 1(4): 367-75 (2006)
2011  
102
Role of zoledronic acid in the prevention and treatment of osteoporosis.
[21594000] Clin Interv Aging 6(-): 89-99 (2011)
2007  
103
Full length parathyroid hormone (1-84) in the treatment of osteoporosis in postmenopausal women.
[18044089] Clin Interv Aging 2(1): 163-74 (2007)
2007  
104
The osteoporotic male: overlooked and undermanaged?
[18044181] Clin Interv Aging 2(3): 305-12 (2007)
2008  
105
Osteoporosis in men: its pathophysiology and the role of teriparatide in its treatment.
[19281056] Clin Interv Aging 3(4): 635-45 (2008)
2010  
106
Glucocorticoid-induced osteoporosis in rheumatic diseases.
[21243296] Clinics (Sao Paulo) 65(11): 1197-205 (2010)
2008  
107
Bone disease and idiopathic hypercalciuria.
[18359394] Semin Nephrol 28(2): 133-42 (2008)
2009  
108
Bone loss in inflammatory disorders.
[19443863] J Endocrinol 201(3): 309-20 (2009)
2011  
109
2011  
110
Clinical utility of clodronate in the prevention and management of osteoporosis in patients intolerant of oral bisphosphonates.
[22087064] Drug Des Devel Ther 5(-): 445-54 (2011)
2010  
111
Zoledronic acid: clinical utility and patient considerations in osteoporosis and low bone mass.
[21151620] Drug Des Devel Ther 4(-): 321-35 (2010)
2008  
112
Cancer treatment-related bone loss: a review and synthesis of the literature.
[18231646] Curr Oncol 15(Suppl 1): S30-40 (2008)
2010  
113
Role of teriparatide in treatment of glucocorticoid-induced osteoporosis.
[21063460] Ther Clin Risk Manag 6(-): 497-503 (2010)
2003  
114
Combined treatment with vitamin k2 and bisphosphonate in postmenopausal women with osteoporosis.
[14584089] Yonsei Med J 44(5): 751-6 (2003)
2008  
115
Teriparatide (recombinant human parathyroid hormone 1-34) in postmenopausal women with osteoporosis: systematic review.
[19099162] Sao Paulo Med J 126(5): 279-84 (2008)
2011  
116
Advances in glucocorticoid-induced osteoporosis.
[21365209] Curr Rheumatol Rep 13(3): 233-40 (2011)
2011  
117
High-dose vitamin D: helpful or harmful?
[21369796] Curr Rheumatol Rep 13(3): 257-64 (2011)
2009  
118
Osteoporosis in children: pediatric and pediatric rheumatology perspective: a review.
[19835571] Pediatr Rheumatol Online J 7(-): 16 (2009)
2011  
119
Nephrolithiasis-associated bone disease: pathogenesis and treatment options.
[21124301] Kidney Int 79(4): 393-403 (2011)
2006  
120
2010  
121
Strontium ranelate in postmenopausal osteoporosis treatment: a critical appraisal.
[21072291] Int J Womens Health 2(-): 1-6 (2010)
2009  
122
Maintaining bone density in patients undergoing treatment for breast cancer: is there an adjuvant benefit?
[19561003] Clin Breast Cancer 9 Suppl 1(-): S18-27 (2009)
2006  
123
Role of dietary sodium in osteoporosis.
[16772639] J Am Coll Nutr 25(3 Suppl): 271S-276S (2006)
2010  
124
Management of glucocorticoid-induced osteoporosis: prevalence, and emerging treatment options.
[21701617] Drug Healthc Patient Saf 2(-): 49-59 (2010)
2011  
125
2011  
126
Non-pharmacological management of osteoporosis: a consensus of the Belgian Bone Club.
[21360219] Osteoporos Int 22(11): 2769-88 (2011)
2011  
127
The impact of pharmacist interventions on osteoporosis management: a systematic review.
[21720894] Osteoporos Int 22(10): 2587-96 (2011)
2010  
128
Vertebral anti-fracture efficacy of strontium ranelate according to pre-treatment bone turnover.
[19436941] Osteoporos Int 21(2): 233-41 (2010)
2011  
129
Optimal use of vitamin D when treating osteoporosis.
[21113692] Curr Osteoporos Rep 9(1): 36-42 (2011)
2008  
130
Correlation of obesity and osteoporosis: effect of fat mass on the determination of osteoporosis.
[17784844] J Bone Miner Res 23(1): 17-29 (2008)
2011  
131
The evidence for efficacy of osteoporosis treatment in men with primary osteoporosis: a systematic review and meta-analysis of antiresorptive and anabolic treatment in men.
[21776371] J Osteoporos 2011(-): 259818 (2011)
2004  
132
Combination and sequential therapy with PTH and bisphosphonates.
[15758282] J Musculoskelet Neuronal Interact 4(4): 407 (2004)
2009  
133
2010  
134
Intravenous bisphosphonates for postmenopausal osteoporosis.
[21526078] J Res Med Sci 15(3): 175-84 (2010)
2011  
135
Clinical review: Effect of endocrine therapies on bone in breast cancer patients.
[21147884] J Clin Endocrinol Metab 96(2): 308-19 (2011)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.


The framed wikipedia articles are from en.wikipedia.org and they are the actual versions; the first is from Nephropedia